• Members Area (login)
  • Contact Us
  • Twitter
  • LinkedIn
Pharmabiotic Research Institute (PRI)
    • PRI
      • Home
      • Purpose & People
      • Representation
      • Partnerships
      • Task Groups
      • Members
      • Pharmabiotics Conference
      • Join Us
    • Microbiome
      • Microbiome Science
      • Regulatory Status
      • Microbiome-based Medicinal Products
    • Regulatory Science
      • EU Landscape
      • Regulatory Framework
      • Regulatory Science & Tools
    • Insights
      • News & Events
      • PRI Publications
      • Member Job Openings
      • Members Area
Select Page

Live Biotherapeutic Products, A Road Map for Safety Assessment

by PRI | Aug 29, 2022 | PRI Publications

Rouanet A, Bolca S, Bru A, Claes I, Cvejic H, Girgis H, Harper A, Lavergne SN, Mathys S, Pane M, Pot B, Shortt C, Alkema W, Bezulowsky C, Blanquet-Diot S, Chassard C, Claus SP, Hadida B, Hemmingsen C, Jeune C, Lindman B, Midzi G, Mogna L, Movitz C, Nasir N,...
Next Entries »

Recent News & Events

  • PRI welcomes Camille Bello as Communication and Membership Manager
  • PRI Board of Director members elects Eleni Tsompanidou as New President
  • Microbiome-based Biomarkers – a multidisciplinary Delphi consensus (The Lancet Microbe)
  • 2024 Pharmabiotics Conference & Partnering – Lille
  • Céline Druart appointed PRI Executive Director following Magali Cordaillat-Simmons’ decision to step down

– Legal Notices –
© PRI 2022. All rights reserved. Copy prohibited unless explicitly authorized. Please contact the PRI.

Pharmabiotic Research Institute (PRI) | European Microbiome Regulatory Science Center
Non-Profit Association (loi 1901) – 1 bis, rue Sénateur Emile Roux, 11100 Narbonne, France

Agence de communication : Frelonbleu